Roche的乳癌药物在一次关键试验中未能改善存活率,刺激其库存下降。 Roche's breast cancer drug failed to improve survival in a key trial, spurring a drop in its stock.

Roche的股权下降超过5%, 因为它的实验性乳癌药物Griedestrant未能在后期试验中达到其主要目标, Roche's shares dropped over 5% after its experimental breast cancer drug giredestrant failed to meet its primary goal in a late-stage trial when combined with Pfizer’s Ibrance as a first-line treatment for hormone receptor-positive, HER2-negative breast cancer. 与标准疗法相比,在统计学上,在无进步生存方面没有显著改善,这标志着药物发育的倒退,并降低了其预期的市场价值。 The trial found no statistically significant improvement in progression-free survival compared to standard therapy, marking a setback for the drug’s development and reducing its projected market value. Roche认为,Giredestrant仍可用于以后阶段使用和其他组合,但分析家认为结果对其肿瘤管道造成重大打击。 While Roche maintains that giredestrant remains viable for later-stage use and other combinations, analysts view the outcome as a major blow to its oncology pipeline.